How Liverpool can afford to sign Alexander Isak this summer
The Reds broke their club transfer record when they brought in Florian Wirtz from Bayer Leverkusen in a deal worth £116.5 million.
Jeremie Frimpong, Armin Pecsi, Milos Kerkez, Giorgi Mamardashvili and most recently Hugo Ektike have also arrived at Anfield, taking their spending to £269m so far.
Given their big outlay this summer, it appears Liverpool will not be able to sign Newcastle United's Alexander Isak.
The Merseyside titans communicated their interest in Isak, but with Newcastle adamant the player was not for sale, they did not submit a formal bid.
The latest is Isak is actively pushing to leave Newcastle, but there are doubts whether Liverpool's finances allow them to spend a huge fee for the Sweden international.
However, the Reds' supporters will be absolutely delighted to hear that their club can afford to spend another £200m and still be compliant with the PSR rules.
This is according to the Daily Mail (July 26, Page 104) who estimated their total income this year at £385m.
Liverpool have been frugal in the previous three transfer windows. Unlike the other big clubs, they signed only one player (Federico Chiesa) for £10m last summer.
Winning the Premier League last season means Arne Slot's side banked £174.9m in prize money and around £83.8m for their run to the last 16 of the Champions League.
Furthermore, their kit deal with Adidas, starting on August 1, is reportedly worth more than £60m per year.
Liverpool have already raised £66m with the sales of Trent Alexander-Arnold, Jarrel Quansah, Nat Phillips and Caoimhin Kelleher.
They could further boost their spending power if they manage to sell Darwin Nunez and Luis Diaz.
It becomes clear Liverpool can afford to sign Isak, but it remains to be seen whether they can tempt Newcastle into selling their best player this summer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 minutes ago
- Forbes
Man Utd's Search For A New Striker Has Narrowed To Two Choices
BOURNEMOUTH, ENGLAND - MAY 10: Ollie Watkins of Aston Villa celebrates following the team's victory ... More during the Premier League match between AFC Bournemouth and Aston Villa FC at Vitality Stadium on May 10, 2025 in Bournemouth, England. (Photo by) Manchester United's hunt for a new centre forward has taken them to a variety of different places. Indeed, the Old Trafford outfit has been linked with countless attackers this summer. Victor Osimhen, Viktor Gyokeres, Nicolas Jackson, Liam Delap and more have all been mentioned as potential United targets. Now, though, the search is finally narrowing. Reports on Tuesday claimed Manchester United now has a choice between Benjamin Sesko and Ollie Watkins. It's believed Sesko could be available for a transfer fee of around $95m while Aston Villa could be convinced to sell Watkins for $55m. Either striker would surely improve the overall quality of Ruben Amorim's forward line. LEIPZIG, GERMANY - FEBRUARY 26: Benjamin Sesko of RB Leipzig scores his team's first goal from the ... More penalty spot during the DFB Cup quarterfinal match between RB Leipzig and VfL Wolfsburg at Red Bull Arena on February 26, 2025 in Leipzig, Germany. (Photo by) Sesko had been strongly linked with a move to Arsenal before the Gunners completed a deal to sign Gyokeres from Sporting CP. Newcastle United is also believed to be admirers of the Slovenian as it faces up to the reality that Alexander Isak could be on his way out of St James' Park to Liverpool this summer. Sesko would be a solid replacement. Watkins is a different sort of option. While Sesko is still thought of as raw potential with the Slovenian still developing, Watkins is proven at Premier League level. He will turn 30 later this year and would be a stop-gap solution for Manchester United to help them build other areas of their team in the short-term. Some United supporters might be disappointed not to land a superstar centre forward, but Watkins has scored 35 Premier League goals over the last two seasons. His all-round game is good enough to work in an Amorim system and there's good reason to believe he would lead the line well for the Old Trafford side. CHICAGO, ILLINOIS - JULY 25: (EXCLUSIVE COVERAGE) Head Coach Ruben Amorim of Manchester United is ... More interviewed after a first team training session as part of their pre-season tour of the USA at Endeavor Health Performance Center on July 25, 2025 in Chicago, Illinois. (Photo by Ash Donelon/Manchester United via Getty Images) Manchester United is at a crucial point in its reconstruction under Amorim. It moved quickly to secure the signings of Matheus Cunha and Bryan Mbeumo from Wolves and Brentford respectively, but still lacks the attacking focal point to bring everything together in the final third. This is why the choice between Sesko and Watkins is so important. Sesko might be the striker with the higher ceiling, but United needs results quickly after a season which saw Amorim's side finish an unprecedented 15th in the Premier League table. Rasmus Hojlund was once seen as Manchester United's number nine of the future. Two years on, the club needs someone who cam contribute in the here and now. That might be Sesko or it could be Watkins.
Bloomberg
2 minutes ago
- Bloomberg
Greggs Shares Fall to Lowest Since Pandemic as Profit Declines
Greggs Plc 's shares fell to the lowest since 2020 after the UK bakery chain reported a drop in profit in the first half of the year. Pre-tax profit fell 14% to £63.5 million ($84.7 million) from a year earlier, according to a statement Tuesday, which Greggs blamed on lower footfall, weather disruption and higher costs. The high street chain, known for its sausage rolls and steak bakes, called it a 'challenging start' to the year.
Associated Press
14 minutes ago
- Associated Press
Hemogenyx Pharmaceuticals PLC Announces Placing to Raise £250,000 and Director's Dealing
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Secures £250,000 to continue its Phase 1 Clinical Trials And Director's Dealing LONDON, UK / ACCESS Newswire / July 29, 2025 / Introduction Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of £250,000 via an allotment to Vladislav Sandler of 133,690 new ordinary shares of £0.01 each ('New Ordinary Shares') at an issue price of 187p, representing a premium to the present market price (the 'Issue Price'). The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ('R/R AML'). As shareholders will be aware, the first two patients have now been treated with HG-CT-1 with the four-week safety trials successfully completed and with encouraging early signs of efficacity. Issuance of the New Ordinary Shares The Company is currently unable to issue and admit New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus. Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO and director of the Company, to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation. Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to a small group of individual investors who made an approach wishing to make a new investment in the Company; they will acquire the Subscription Shares from Mr Sandler at the price of 187p per share. Warrants Concurrent with the purchase of the New Ordinary Shares, the new investor group will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 187p ('Exercise Price'), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price. Total Voting Rights Application will be made for the 133,690 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to theFCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 7 August 2025 ('Admission'). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 4,727,229. The above figure of 4,727,229 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company will keep the market informed of future developments as trials proceed. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: 'We are pleased to have attracted funding from this group of investors at a premium to the current price - this reflects their confidence in the progress made by the Company to date and in the long-term prospects of Hemogenyx. The fact that the raise was completed at a premium to the market price demonstrates this confidence and shows that they see considerable upside potential in our share price as we advance HG-CT-1 through clinical development. .' UK Market Abuse Regulation (UK MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder. Director's Dealing Notification Enquiries: About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City . The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Hemogenyx Pharmaceuticals PLC press release
